Co-Author
This page shows the publications co-authored by Kevin Oh and Helen Shih.
Connection Strength
4.724
-
Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):252-266.
Score: 0.222
-
Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. J Neurooncol. 2020 May; 148(1):81-88.
Score: 0.217
-
Post-operative radiation therapy to the surgical cavity with standard fractionation in patients with brain metastases. Sci Rep. 2020 04 14; 10(1):6331.
Score: 0.217
-
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. Cancer Med. 2020 01; 9(1):3-11.
Score: 0.211
-
Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. World Neurosurg. 2020 Jan; 133:e804-e812.
Score: 0.210
-
Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiother Oncol. 2020 01; 142:154-161.
Score: 0.209
-
Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol. 2019 08; 137:95-101.
Score: 0.204
-
Patterns of Failure Among Patients With Low-grade Glioma Treated With Proton Radiation Therapy. Pract Radiat Oncol. 2019 Jul - Aug; 9(4):e356-e361.
Score: 0.201
-
Hypopituitarism After Cranial Irradiation for Meningiomas: A Single-Institution Experience. Pract Radiat Oncol. 2019 May; 9(3):e266-e273.
Score: 0.200
-
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
Score: 0.197
-
Proton Stereotactic Radiosurgery for Brain Metastases: A Single-Institution Analysis of 370 Patients. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):820-829.
Score: 0.189
-
Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):624-629.
Score: 0.188
-
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. J Neurooncol. 2018 Jun; 138(2):299-306.
Score: 0.187
-
Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg. 2018 04; 128(4):1123-1132.
Score: 0.179
-
The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):391-397.
Score: 0.178
-
Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol. 2016 Jan; 126(1):157-164.
Score: 0.161
-
Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg. 2016 Jan; 124(1):106-14.
Score: 0.157
-
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. J Neurooncol. 2015 May; 123(1):75-84.
Score: 0.154
-
Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer. 2015 May 15; 121(10):1712-9.
Score: 0.151
-
Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015 Feb; 17(2):296-302.
Score: 0.146
-
Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer. 2014 Jan 15; 120(2):238-43.
Score: 0.138
-
Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol. 2013 Dec; 115(3):411-9.
Score: 0.138
-
Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):e167-72.
Score: 0.117
-
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954.
Score: 0.060
-
Initial Approach to the Patient with Multiple Newly Diagnosed Brain Metastases. Neurosurg Clin N Am. 2020 Oct; 31(4):505-513.
Score: 0.056
-
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
Score: 0.055
-
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
Score: 0.055
-
Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas. Neurosurgery. 2019 11 01; 85(5):E910-E916.
Score: 0.053
-
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. Oncologist. 2019 05; 24(5):671-679.
Score: 0.050
-
Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist. 2019 02; 24(2):193-201.
Score: 0.049
-
C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1024-1028.
Score: 0.048
-
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 04; 13(4):550-558.
Score: 0.047
-
Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol. 2016 Feb; 11(2):256-60.
Score: 0.040
-
Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol. 2016 06; 18(6):863-72.
Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.